Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
237.04
-0.49 (-0.21%)
At close: Jul 16, 2026, 4:00 PM EDT
237.53
+0.49 (0.21%)
Pre-market: Jul 17, 2026, 8:08 AM EDT

Axsome Therapeutics Stock Forecast

Stock Price Forecast

According to 20 analysts polled by S&P Global, Axsome Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $280.39. The average 1-year stock price forecast is 18.29% higher than the current stock price, while the lowest is $242 (+2.09%) and the highest is $380 (+60.31%).

Price Target: $280.39 (+18.29%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$242$280.39$274$380
Change+2.09%+18.29%+15.59%+60.31%

Analyst Ratings

The average analyst rating for Axsome Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingFeb '26Mar '26Apr '26May '26Jun '26Jul '26
Strong Buy171717171716
Buy333333
Hold111111
Sell000000
Strong Sell000000
Total212121212120

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Jefferies
Jefferies
Buy
Maintains
$200$380
BuyMaintains$200$380+60.31%Jul 16, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$290
BuyReiterates$290+22.34%Jul 15, 2026
Piper Sandler
Piper Sandler
Buy
Reiterates
$258
BuyReiterates$258+8.84%Jul 14, 2026
Mizuho Securities
Mizuho Securities
Buy
Reiterates
$310
BuyReiterates$310+30.78%Jul 13, 2026
Bank of America Securities
Bank of America Securities
Buy
Maintains
n/a
BuyMaintainsn/an/aJul 10, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
978.95M
from 638.50M
Increased by 53.32%
Revenue Next Year
1.59B
from 978.95M
Increased by 62.91%
EPS This Year
-1.70
from -3.47
EPS Next Year
5.87
from -1.70
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
-50.04M270.60M385.69M638.50M978.95M
Revenue Growth
--440.80%42.53%65.55%53.32%
Gross Profit
-45.94M244.54M352.39M591.02M902.43M
Gross Margin
-91.81%90.37%91.37%92.56%92.18%
Operating Income
-124.71M-175.40M-182.91M-252.44M-169.24M-98.07M
Net Income
-130.40M-187.13M-239.24M-287.22M-183.17M-107.36M
EPS
-----3.47-1.70
Free Cash Flow
-59.52M-43.82M-87.21M-38.10M-29.42M-60.42M
No. Analysts
-----20
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High1.1B
Avg979.0M
Low867.6M

Revenue Growth

Revenue Growth202620272028
High
75.3%
Avg
53.3%
Low
35.9%

EPS Forecast

EPS202620272028
High1.30
Avg-1.70
Low-3.35

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-